Jordan Gauthier

Jordan Gauthier

Jordan Gauthier, MD, MSc

12 Years of Experience
Physician
Seattle Cancer Care Alliance
Assistant Professor, Division of Medical Oncology
University of Washington School of Medicine
Physician
UW Medicine
Assistant Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Clinical expertise
Blood cancers, bone marrow transplantation, CAR T-cell therapy
Request an Appointment
Located at
“

I see every patient encounter as a precious opportunity to help, engage and learn.

”
— Dr. Gauthier

Why do you practice hematology-oncology?

The meaningful connections I make with patients are part of what I enjoy about this specialty. One of my favorite memories is bonding with a patient who was undergoing a bone marrow transplant. He was a talented engineer and would show me pictures of all the amazing objects he built. He also taught me all about Japanese dog breeds and, I hope, I was able to teach him about the workings of the immune system. Not only did we develop an easy rapport, but we learned from each other, and I was grateful I could accompany him on his journey.

Jordan Gauthier

Specialties and clinical expertise
The branch of medicine a provider practices and their areas of focus

Blood cancers

I am a hematologist-oncologist who specializes in treating blood cancers such as leukemia and lymphoma. My expertise includes caring for patients receiving blood and bone marrow transplantation (BMT) as well as immunotherapies.

Much of my research so far has been focused on improving outcomes for patients treated with BMT or chimeric antigen receptor (CAR) T-cell therapy. This cellular immunotherapy engineers T cells (a type of immune cell) to attack tumors. Through my work, I have identified factors that can help predict the success of CAR T-cell therapy for patients who have leukemia and lymphoma. My background also includes international research collaborations through the European Society for Blood and Marrow Transplantation.

Diseases treated

Acute Lymphocytic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Graft versus Host Disease
Myeloproliferative Disorder (MPD)
See more See less

What’s it like to work with you?

I strive to be mindful of your life story beyond your disease, learning about your goals for care, your support system and what activities bring you joy. Depending on your interest and level of comfort, I like to share with you what’s going on beneath the surface of a symptom or disease process, discussing the biology of what’s happening so you know why you aren’t feeling well — or why you’re feeling better. As much as possible, I try to prepare you for what to expect during the treatment process so that you aren’t caught off guard by symptoms or side effects.

Education, experience and certifications

Undergraduate Degree
University of Rennes, France
Medical Degree
University of Rennes, France
Residency
Henri Warembourg Faculty of Medicine, Lille, France
Fellowship
Fred Hutch, Immunotherapy Integrated Research Center
Other
MSc, University of Lille, France

Languages

English, French

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Study No: NCT02503423
Phase: Phase I/II
View Trial
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Study No: NCT02396134
Phase: Phase II
View Trial
Safety Study of SEA-CD40 in Cancer Patients
Study No: NCT02376699
Phase: Phase I
View Trial
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Study No: NCT03037645
Phase: Phase I/II
View Trial
See more clinical trials

Press and news

SCCA providers are often asked to give their medical advice for press and news publications. Read articles by or about this SCCA provider.
Ibrutinib Plus CAR T-Cell Therapy Boosts Response in CLL
By OncLive - Published February 22, 2019
Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL
By ecancer - Published December 4, 2018

Publications

Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
See more publications

Awards

European Bone Marrow Transplantation Young Ambassador, 2017
This award recognizes talented scientists, physicians and nurses who are rising stars in the field of bone marrow transplantation.
Fred Hutchinson Cancer Research Center IIRC Fellowship Award
Dr. Gauthier was the first immunotherapy clinical fellow to serve in a joint Immunotherapy Integrated Research Center (IIRC) program in clinical and laboratory research.
To top